[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Lee YY, Wong KT, King AD, Ahuja AT: Imaging of salivary gland tumours. Eur J Radiol; 2008 Jun;66(3):419-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of salivary gland tumours.
  • Salivary gland neoplasms account for <3% of all tumors.
  • Most of them are benign and parotid gland is the commonest site.
  • As a general rule, the smaller the involved salivary gland, the higher is the possibility of the tumor being malignant.
  • The role of imaging in assessment of salivary gland tumour is to define intra-glandular vs. extra-glandular location, detect malignant features, assess local extension and invasion, detect nodal metastases and systemic involvement.
  • For lesions in the superficial parotid and submandibular gland, ultrasound is an ideal tool for initial assessment.
  • If deep tissue extension is suspected or malignancy confirmed on cytology, an MRI or CT is mandatory to evaluate tumour extent, local invasion and perineural spread.
  • For all tumours in the sublingual gland, MRI should be performed as the risk of malignancy is high.
  • For lesions of the deep lobe of parotid gland and the minor salivary glands, MRI and CT are the modalities of choice.
  • Ultrasound has limited visualization of the deep lobe of parotid gland which is obscured by the mandible.
  • Minor salivary gland lesions in the mucosa of oral cavity, pharynx and tracheo-bronchial tree, are also not accessible by conventional ultrasound.
  • Recent study suggests that MR spectroscopy may differentiate malignant and benign salivary gland tumours as well as distinguishing Warthin's tumor from pleomorphic adenoma.
  • Similarly, the role of nuclear medicine and PET scan, in imaging of parotid masses is limited.
  • Sialography is used to delineate the salivary ductal system and has limited role in assessment of tumour extent.
  • [MeSH-major] Diagnostic Imaging. Salivary Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337041.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 44
  •  go-up   go-down


2. Epivatianos A, Poulopoulos A, Kayavis I, Papanayotou P: Tumor-associated glycoprotein 72 (TAG-72) expression in salivary gland neoplasia: an immunohistochemical study using the monoclonal antibody (MAb) CC49. Oral Dis; 2000 Mar;6(2):112-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated glycoprotein 72 (TAG-72) expression in salivary gland neoplasia: an immunohistochemical study using the monoclonal antibody (MAb) CC49.
  • OBJECTIVES: The purpose of this study was to investigate immunohistochemically the expression of tumor-associated glycoprotein 72 (TAG-72) using the monoclonal antibody (MAb) CC49 in salivary gland neoplasia and normal salivary glands in an attempt to determine the potential usefulness of MAb CC49 in diagnostic and therapeutic applications.
  • MATERIALS AND METHODS: Eighty-six specimens (21 benign tumors, 41 malignant, and 24 normal salivary glands), fixed in 10% formalin and embedded in paraffin, were retrieved from the files of the Department of Oral Medicine and Oral Pathology at the Dental School of Aristotle University, Thessaloniki, Greece, and were retrospectively studied with hematoxylin and eosin and with the streptavidin-biotin-complex method using the MAb CC49.
  • RESULTS: Strong immunoreactivity for TAG-72 was observed in salivary duct carcinoma, adenocarcinoma, papillary cystadenocarcinoma, low-grade mucoepidermoid carcinoma, normal submandibular, sublingual, and minor salivary glands.
  • Weak or no immunoreactivity was found in adenoid cystic carcinoma, basal cell adenocarcinoma, polymorphous low-grade adenocarcinoma, and normal parotid gland.
  • CONCLUSIONS: Our results suggest the potential use of MAb CC49 in the differential diagnosis of some salivary gland neoplasms in which their histopathologic features overlap, and in the radiation immunolocalization and immunotherapy of malignant tumors that are localized in the parotid gland.
  • [MeSH-major] Antibodies, Monoclonal. Antibodies, Neoplasm. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Glycoproteins / analysis. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Carcinoma / genetics. Carcinoma / pathology. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / genetics. Carcinoma, Mucoepidermoid / pathology. Coloring Agents. Cystadenocarcinoma, Papillary / genetics. Cystadenocarcinoma, Papillary / pathology. Eosine Yellowish-(YS). Fluorescent Dyes. Gene Expression Regulation, Neoplastic. Hematoxylin. Humans. Immunoenzyme Techniques. Immunohistochemistry. Parotid Gland / cytology. Parotid Gland / metabolism. Retrospective Studies. Salivary Glands / cytology. Salivary Glands / metabolism. Salivary Glands, Minor / cytology. Salivary Glands, Minor / metabolism. Sublingual Gland / cytology. Sublingual Gland / metabolism. Submandibular Gland / cytology. Submandibular Gland / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. HEMATOXYLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10702789.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / B72.3 antibody; 0 / Biomarkers, Tumor; 0 / Coloring Agents; 0 / Fluorescent Dyes; 0 / Glycoproteins; 0 / tumor-associated antigen 72; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


Advertisement
3. Vuhahula EA: Salivary gland tumors in Uganda: clinical pathological study. Afr Health Sci; 2004 Apr;4(1):15-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland tumors in Uganda: clinical pathological study.
  • BACKGROUND: The incidence of salivary gland tumors is claimed to be influenced by geographical and racial factors.
  • The pathological classification and nomenclature of salivary gland tumors as defined by WHO classification (1991), is accepted world-wide but little is available in the literature regarding the spectrum of salivary gland tumors in Africa in the basis of this classification.
  • OBJECTIVE: To outline the clinicopathological features of salivary gland tumors in Uganda.
  • SETTING: Makerere University, Faculty of Medicine, Department of Pathology.
  • METHODS: All epithelial tumors from major and minor salivary glands accessioned from 1979 to 1988 were analyzed in respect to sex and age of patients, anatomical location of the tumor and histological type.
  • The histological diagnosis of each individual tumor was based on the 1991 WHO classification of salivary gland tumors.
  • RESULTS: During the span of 10 years, 268 cases of salivary gland tumors were diagnosed.
  • Thirty four percent of tumors originated from the parotid, 33.2% from the submandibular and 32.8% from minor salivary glands.
  • No tumor was implicated from the sublingual gland.
  • There were a total of 125 (46.6%) malignant tumors and 143 (53.4%) benign tumors.
  • The mean age of patients with malignant lesions (43.1 years; SD=16.75; median=44.00 years) was 9.6 years older than those with benign tumors (mean=33.5 years; SD=16.0; median=30.00 years).
  • Pleomorphic adenoma was the most common benign tumor (74.8%), followed by myoepithelioma (9.8%).
  • No Whartin's tumor was encountered.
  • CONCLUSION: The pattern of distribution of salivary gland tumors in black African population seems to differ from that of Western series in that;.
  • i) females are more affected than males, ii) there is a low proportion of tumors from the parotid gland and high proportion of tumors from the submandibular and minor salivary glands, iii) the parotid and minor salivary gland tumors have more probability of being malignant than those tumors from the submandibular gland iv) the newly categorized pathological entities are common and v) Whartin's tumor is extremely rare in black African population.
  • [MeSH-major] Salivary Gland Neoplasms / ethnology
  • [MeSH-minor] Adolescent. Adult. African Continental Ancestry Group. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. European Continental Ancestry Group. Female. Humans. Infant. Male. Middle Aged. Neoplasm Metastasis. Sex Distribution. Uganda / epidemiology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] West Afr J Med. 1999 Jul-Sep;18(3):179-82 [10593153.001]
  • [Cites] Histopathology. 2000 Sep;37(3):260-3 [10971702.001]
  • [Cites] Odontostomatol Trop. 2002 Sep;25(99):19-22 [12430350.001]
  • [Cites] Br J Surg. 1968 Apr;55(4):284-8 [4296231.001]
  • [Cites] Am J Clin Pathol. 1977 Mar;67(3):272-8 [842502.001]
  • [Cites] Br J Cancer. 1964 Dec;18:649-54 [14269339.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] East Afr Med J. 1992 Sep;69(9):525-30 [1286637.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):701-7 [9066605.001]
  • [Cites] Dakar Med. 1998;43(1):60-4 [9827159.001]
  • [Cites] Cancer. 1964 Oct;17:1310-22 [14236765.001]
  • [Cites] Cancer. 1980 Nov 15;46(10):2328-34 [7427875.001]
  • (PMID = 15126188.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC2141656
  •  go-up   go-down






Advertisement